1. Home
  2. ULY vs BIAF Comparison

ULY vs BIAF Comparison

Compare ULY & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Urgent.ly Inc.

ULY

Urgent.ly Inc.

HOLD

Current Price

$2.29

Market Cap

4.0M

Sector

N/A

ML Signal

HOLD

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

HOLD

Current Price

$1.64

Market Cap

6.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ULY
BIAF
Founded
2013
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0M
6.6M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
ULY
BIAF
Price
$2.29
$1.64
Analyst Decision
Strong Buy
Hold
Analyst Count
2
1
Target Price
$11.50
N/A
AVG Volume (30 Days)
41.2K
105.9K
Earning Date
11-12-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$127,932,000.00
$6,776,739.00
Revenue This Year
N/A
N/A
Revenue Next Year
$18.95
$20.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.74
$1.25
52 Week High
$17.99
$46.53

Technical Indicators

Market Signals
Indicator
ULY
BIAF
Relative Strength Index (RSI) 49.99 44.37
Support Level $1.75 $1.34
Resistance Level $1.93 $1.54
Average True Range (ATR) 0.16 0.15
MACD 0.05 0.05
Stochastic Oscillator 52.69 66.08

Price Performance

Historical Comparison
ULY
BIAF

About ULY Urgent.ly Inc.

Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Share on Social Networks: